as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences reported FY2026 consolidated revenue of Rs 3,129.42 crore, up 8.15% from Rs 2,893.64 crore in FY2025. Net profit surged 72.8% to Rs 647.51 crore versus Rs 374.67 crore last year, driven by a one-time deferred tax credit of Rs 150 crore from opting into the new concessional tax regime and improved operating margins (27.11% vs 24.89%). The Board declared an interim dividend of Rs 7.21 per share (721%) for FY2027. Exceptional items of Rs 17.24 crore were recorded due to increased gratuity and leave liabilities from new labour codes. The auditor gave an unmodified (clean) opinion.
The strong PAT growth of 73% and margin expansion are positive signals for shareholders. The one-time tax benefit inflated profits; underlying operational performance showed steady improvement. The generous 721% dividend signals confidence in cash flows.